文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

遗传和实验室发现对抗合成酶综合征在匈牙利队列中的临床病程的影响。

Effect of Genetic and Laboratory Findings on Clinical Course of Antisynthetase Syndrome in a Hungarian Cohort.

机构信息

University of Debrecen, Faculty of Medicine, Division of Clinical Immunology, Móricz Zs. krt. 22, 4032 Debrecen, Hungary.

University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Nagyerdei krt. 98, 4032 Debrecen, Hungary.

出版信息

Biomed Res Int. 2018 Oct 25;2018:6416378. doi: 10.1155/2018/6416378. eCollection 2018.


DOI:10.1155/2018/6416378
PMID:30498759
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6222225/
Abstract

The aim of this study was to determine the clinical, serological, and genetic features of anti-Jo-1 positive antisynthetase patients followed by a Hungarian single centre to identify prognostic markers, which can predict disease phenotypes and disease progression. It was a retrospective study using clinical database of 49 anti-Jo-1 positive patients. 100% of patients exhibited myositis, 73% interstitial lung disease, 88% arthritis, 65% Raynaud's phenomenon, 43% fever, 33% mechanic's hand, and 12% dysphagia. We could detect significant correlation between anti-Jo-1 titer and the CK and CRP levels at disease onset and during disease course. HLA DRB1⁎03 positivity was present in 68.96% of patients, where the CK level at diagnosis was significantly lower compared to the HLA DRB1⁎03 negative patients. HLA DQA1⁎0501-DQB1⁎0201 haplotype was found in 58.62% of patients, but no significant correlation was found regarding any clinical or laboratory features. Higher CRP, ESR level, RF positivity, and the presence of fever or vasculitic skin lesions at the time of diagnosis indicated a higher steroid demand and the administration of higher number of immunosuppressants during the follow-up within anti-Jo-1 positive patients. The organ involvement of the disease was not different in HLA-DRB1⁎0301 positive or negative patients who were positive to the anti-Jo-1 antibody; however, initial CK level was lower in HLA-DRB1⁎0301 positive patients. Distinct laboratory and clinical parameters at diagnosis could be considered as prognostic markers.

摘要

本研究旨在确定接受匈牙利单一中心随访的抗 Jo-1 阳性抗合成酶患者的临床、血清学和遗传学特征,以确定可预测疾病表型和疾病进展的预后标志物。这是一项回顾性研究,使用了 49 名抗 Jo-1 阳性患者的临床数据库。100%的患者表现出肌炎,73%的患者出现间质性肺病,88%的患者出现关节炎,65%的患者出现雷诺现象,43%的患者出现发热,33%的患者出现技工手,12%的患者出现吞咽困难。我们可以检测到抗 Jo-1 滴度与疾病发病时和疾病过程中 CK 和 CRP 水平之间存在显著相关性。68.96%的患者存在 HLA DRB1⁎03 阳性,与 HLA DRB1⁎03 阴性患者相比,这些患者的 CK 水平在诊断时显著降低。58.62%的患者存在 HLA DQA1⁎0501-DQB1⁎0201 单倍型,但与任何临床或实验室特征均无显著相关性。较高的 CRP、ESR 水平、RF 阳性以及诊断时存在发热或血管炎皮肤损伤,表明抗 Jo-1 阳性患者在随访期间需要更高剂量的类固醇和更多免疫抑制剂的治疗。在 HLA-DRB1⁎0301 阳性或阴性的抗 Jo-1 抗体阳性患者中,疾病的器官受累没有差异;然而,HLA-DRB1⁎0301 阳性患者的初始 CK 水平较低。在诊断时的不同实验室和临床参数可作为预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d8/6222225/e471cb836a62/BMRI2018-6416378.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d8/6222225/e471cb836a62/BMRI2018-6416378.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70d8/6222225/e471cb836a62/BMRI2018-6416378.001.jpg

相似文献

[1]
Effect of Genetic and Laboratory Findings on Clinical Course of Antisynthetase Syndrome in a Hungarian Cohort.

Biomed Res Int. 2018-10-25

[2]
[The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort].

Orv Hetil. 2016-4-10

[3]
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group.

Clin Rev Allergy Immunol. 2017-2

[4]
Myositis-related interstitial lung disease and antisynthetase syndrome.

J Bras Pneumol. 2011

[5]
Interstitial lung disease in a patient with antisynthetase syndrome and no myositis.

Clin Rheumatol. 2007-1

[6]
Clinical and prognostic associations of anti-Jo-1 antibody levels in patients with antisynthetase syndrome.

Respir Res. 2024-5-29

[7]
Clinical manifestations and treatment of antisynthetase syndrome.

Best Pract Res Clin Rheumatol. 2020-8

[8]
Clinical characteristics of Vietnamese patients with idiopathic inflammatory myopathies and autoantibodies to aminoacyl-transfer RNA synthetases.

Int J Rheum Dis. 2021-5

[9]
Clinical, Serological, and Genetic Characteristics of a Hungarian Myositis-Scleroderma Overlap Cohort.

Biomed Res Int. 2022

[10]
Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome.

ARP Rheumatol. 2022-11-1

引用本文的文献

[1]
Clinical, Serological, and Genetic Characteristics of a Hungarian Myositis-Scleroderma Overlap Cohort.

Biomed Res Int. 2022

[2]
Idiopathic inflammatory myopathies.

Nat Rev Dis Primers. 2021-12-2

[3]
Idiopathic inflammatory myopathies.

Nat Rev Dis Primers. 2021-12-2

[4]
Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.

Clinicoecon Outcomes Res. 2021-6-8

[5]
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.

BMC Cancer. 2021-6-2

本文引用的文献

[1]
Autoantibodies in myositis.

Nat Rev Rheumatol. 2018-4-20

[2]
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Arthritis Rheumatol. 2017-10-27

[3]
Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria.

Ann Rheum Dis. 2018-8

[4]
The EuroMyositis registry: an international collaborative tool to facilitate myositis research.

Ann Rheum Dis. 2018-1

[5]
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Ann Rheum Dis. 2017-5

[6]
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study.

Autoimmun Rev. 2017-1-29

[7]
Idiopathic inflammatory myositis.

Best Pract Res Clin Rheumatol. 2016-5-26

[8]
[The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort].

Orv Hetil. 2016-4-10

[9]
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group.

Clin Rev Allergy Immunol. 2017-2

[10]
Myositis-specific autoantibodies: an important tool to support diagnosis of myositis.

J Intern Med. 2015-11-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索